Association between hyperhomocysteinemia and preeclampsia
DOI:
https://doi.org/10.18597/rcog.653Keywords:
preeclampsia, homocystein, hyperhomocysteinemiaAbstract
OBJECTIVE: To explore the association between posprandial elevated serum levels of homocystein and preeclampsia and related complications before 35 weeks of gestational age.
METHODOLOGY: Cross sectional study on 109 pregnant patients before 35 weeks of gestational age (group I, n = 55 pre-eclamptic patients (90,9% severe cases), and group II, n = 54 non pre-eclamptic patients) of the hospitals Universitario San Vicente de Paúl and General de Medellín, from September 1st, 1999 to September 1st, 2000.
RESULTS: There were no differences between both groups when analyzing general characteristics. There was no correlation between homocystein, measured by fluorescent polarized immunoassay (FPIA) with pregnant patient age, gestational age no parity (Spearman's rho -0,057 - 0,074 - 0,17 respectively).
There was a significant difference between medians of the homocystein concentration in compared groups: in G I it was 11,8 and 8,8 micromol/L in GII (p<0,01).
Patients with homocystein level in the last quartile (>11.2 micromol/L) have a risk 9,67 times higher when compared with patients in the first quartile (Homocystein < 7,1) to present preeclampsia (p = 0,001). Percentile 95 for norm-tense pregnant patients was 13,025 micromol/L. This level was established like an end point for hyperhomocysteinemia definition in pregnant women; 25 (45,5%) in G I and 2 (3,37%) in G II of the patients were positive for hyperhomocysteinemia, odds ratio (OR) 21,67 (confidence interval 95% 4,48 - 142,66, p< 0,001).
Fourteen group I patients had complications attributable to preeclampsia, 6 were positive women for hyperhomocysteinemia compared to 19 positive patients for hyper homocysteinemia of 41 without complications in the same group (p = 0,397).
Thirteen of 25 intrauterine growth restriction (IUGR) events in G I compared to 12 patients of 30 without IUGR, were positive patients for hyperhomocysteinemia (p = 0,37). Six newborns of 26 women in group II that ended gestation in the source hospitals, presented intrauterine grow restriction but their mothers were negative for hyperhomocysteinemia.
CONCLUSION: hyperhomocysteinemia was defined in pregnancy above p95, HC > 13,025 micromol/L and an association, though not causal, between hyperhoocysteinemia and preeclampsia was found.
Author Biographies
Jorge Mario Gómez Jiménez
Jhon Jairo Zuleta Tobón
Germán Campuzano Mayo
Carlos Mario Córdoba Gómez
References
E.U. Population Reference Bureau (PRB). Resumen de las conclusiones del Consejo Nacional de Investigación de la Academia Nacional de Ciencias de los E.U, "Cómo mejorar la salud reproductiva de los países en desarrollo". Washington; 1997.
Presidencia de la República, Departamento Nacional de Planeación, Ministerio de Salud y otros. "Mortalidad Materna en Colombia". Santafé de Bogotá; 1996.
Ness R, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365-70.
Stone J. Risk factors for severe preeclampsia. Obstet Gynecol;1994;83:357-61.
Sibai B. Aspectos inmunitarios de la preeclampsia. Clín Obstét Ginecol 1991:27-33.
Lockwood Ch, Rand J. The immunobiology and obstetrical consequences of antiphospholipid antibodies. Obstet Gynecol Surv 1994;49:432-40.
Molina J. Anticuerpos Antifosfolípidos. IATREIA 1992;5:160-1
Dekker G, de Vries J, Doelitzsch P, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
Kupferminc M, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340: 9-13.
Blummenfield Z, Brenner B. Thrombophilia-associated pregnancy wastage. Fertil Steril 1999;72:765-74.
Córdoba A, Blanco F, González F. Hiperhomocisteinemia, un nuevo marcador de riesgo vascular: territorios vasculares afectados; papel en la patogénesis de la arterioesclerosis y la trombosis y tratamiento. Med Clin (Barc) 1997;109:715-25.
Pampus M, Wolf H, Buller H. Underlying disorders associated with severe preeclampsia and Hellp syndrome. Am J Obstet Gynecol 1997;176:S26.
Rajkovic A, Mahomed K, Malinov R. Elevated homocysteine levels with preeclampsia. Obstet Gynecol 1997;90:168-71.
Rajkovic A, Mahomed K, Malinov R, et al. Plasma homocysteine concentrations in eclamptic and preeclamptic African women postpartum. Obstet Gynecol 1999;94:355-60.
Laivuori H, Kaaja R, Turpeinem U, et al. Plasma homocystein levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999;93:489-93.
Powers R, Evans R, Majors A, et al. Plasma homocystein concentration is increased in preeclampsia and is associated with evidence of endothelial activation. Am J Obstet Gynecol 1998;179:1605-11.
Raijmakers M, Zusterzeel P, Steegers E, et al. Plasma Thiol status in preeclampsia. Obstet Gynecol 2000;95:180-4.
Ray JG, Laskin CA. Folic acid and homocystein metabolic effects and risk of placental abruption, preeclampsia and spontaneous pregnancy loss. A systematic review. Placenta; 1999;20:519-29.
Wang J, Trudenger BJ, Duarte N. Elevated circulating homocystein levels in placental vascular disease and associated preeclampsia. Br J Obstet Gynecol; 2000;107:935-8.
Sorensen TK, Malino MR, Williams MA. Elevated second trimester serum homocystein levels and subsequents risk of preeclampsia. Gynecol Obstet Invest; 1999;48:98-103.
Leeda M, Riyas I, de Vries JIP, et al. Effects of folic acid and vitamin B6 supplementation on women with hyperhomocysteinemia and history of preeclampsia or fetal grow restriction. Am J Obstet Gynecol 1997;179:135-9.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
